Accelevir Diagnostics is a Maryland biotechnology company developing innovative assays for ultra-rare analytes in infectious disease and beyond. Our team brings expertise in virology, immunology, and assay commercialization. We employ advanced ddPCR, qPCR, and sequencing as well as culture-based approaches to develop scalable assays for difficult to detect pathogens that can support the continuum from basic research through clinical trials. We are currently focused on advancing new assays for persistent HIV-1 and other clinically important viral infections. To date, we have received over $5M in federal, state and private funding to advance our assays. We are actively working with leading academic and bio-pharma groups to provide our assays in support of translational research and early-stage clinical trials.